Contact lens care using chlorhexidine acetate with ethyl-6-O-decanoyl-glucoside: a comparative clinical and bacteriological study.
OBJECTIVE
We compared Ethyl-6-O-decanoyl-glucoside 0.005% (EDG) combined with 0.00025% chlorhexidine acetate (EDGC) to a commercial polyaminpropylbiguanide (PAPB).


METHODS
Fifty-nine subjects wearing both ionic and non-ionic contact lenses for 8-16 hours daily used either EDGC or PAPB as a cleaning and disinfectant agent. Neither mechanical nor separate cleaning agents were employed. The study period was for 8 weeks. The following symptoms were compared for each solution: blurred vision, dryness, foreign body sensation, redness, and dirty lenses. The following signs were also compared for each solution: conjunctival hyperemia, papillary hypertrophy, corneal deposits, purulence, limbal vascularization, subepithelial scarring, visual acuity, bulbar hyperemia, and tear breakup time.


RESULTS
After 8 weeks, 52% of the subjects in the EDGC group showed no evidence of corneal or conjunctival abnormalities. In contrast, only 19% of the subjects in the PAPB group showed no abnormalities of the conjunctiva or cornea (P = 0.012). After 8 weeks, 25% of the EDGC group showed evidence of papillary hypertrophy, whereas 50% of the PAPB group showed similar findings (P = 0.007). In addition, after 8 weeks of wear, 21% of the subjects using EDGC had positive conjunctival cultures, whereas the rate of positive cultures in the PAPB group was 50% (P = 0.035). At the conclusion of the study, the protein contents of the lenses were 131 micrograms +/- 48 micrograms (N = 29) in the EDGC group and 185 micrograms +/- 65 micrograms (N = 26) in the PAPB group (P = 0.001).


CONCLUSIONS
Subjects using EDGC had fewer pathological findings than subjects using PAPB as their cleaning and disinfecting agent. The mechanism by which EDGC reduced the rate of papillary hypertrophy needs further investigation.
Vaahtoranta-Lehtonen
H H
HH
Finnsusp Ltd., Lieto, Finland.
Lehtonen
O P
OP
Peltola
O
O
D000328:Adult; D001419:Bacteria / Q000187:drug effects*; D001431:Bacteriological Techniques; D001645:Biguanides / Q000494:pharmacology; D002710:Chlorhexidine / Q000494:pharmacology*; D003228:Conjunctiva / Q000382:microbiology; D003234:Conjunctivitis, Bacterial / Q000382:microbiology / Q000517:prevention & control; D018639:Contact Lens Solutions / Q000494:pharmacology*; D003263:Contact Lenses, Hydrophilic / Q000382:microbiology*; D003315:Cornea / Q000382:microbiology; D003902:Detergents / Q000494:pharmacology; D004311:Double-Blind Method; D004338:Drug Combinations; D015818:Eye Infections, Bacterial / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D005960:Glucosides / Q000494:pharmacology*; D006801:Humans; D007634:Keratitis / Q000382:microbiology / Q000517:prevention & control; D008297:Male; D011310:Preservatives, Pharmaceutical / Q000494:pharmacology
D001645:Biguanides; D018639:Contact Lens Solutions; D003902:Detergents; D004338:Drug Combinations; D005960:Glucosides; D011310:Preservatives, Pharmaceutical; C102302:ethyl-6-O-decanoyl glucoside; C064420:polyaminopropylbiguanide; D002710:Chlorhexidine